Home / Resources / 臨床試験情報の開示義務違反が製薬企業のM&Aに及ぼす影響とは？
WHITE PAPER | OCT 07, 2025

臨床試験情報の開示義務違反が製薬企業のM&Aに及ぼす影響とは？

M&Aを検討する際に注意すべき「非開示のレッドフラッグ」とは？また、デューデリジェンスの過程で企業が自社を守るために取るべき対策とは？

フォームにご入力いただいた方全員に、ホワイトペーパーを無料でプレゼント！

PDF preview of Clinical Trial Disclosure Noncompliance: What Is Its Impact on Pharma M&As? white paper, available for download.
Citeline may contact you about relevant products, services, and content. To opt out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.
It breaks the trust within the patient community if a company is hiding the results of a trial, or maybe hiding information related to the trial.
Sahil Khatter, Principal Project Manager, Citeline
関連製品
Automated submissions to Clinical Trials
TrialScope Disclose
臨床試験情報開示の管理において最も広く信頼されているソリューション
Sponsors accessing TrialScope Intelligence for regulations and requirements.
TrialScope Intelligence
国際的な臨床試験情報開示のコンプライアンスに必要な重要な規制知識を一元化した対話型のリポジトリ
Citeline professionals providing hands on disclosure services.
TrialScope Disclosure Services
規制文書の作成から試験登録、結果の公開まで、実務に即した臨床試験開示サービス

関連コンテンツ

''
DEC 01, 2024
eBook
薬事規制関連支援サービス

Citeline Maturity Model for Clinical Trial Disclosure

The Citeline Maturity Model for Clinical Trial Disclosure is critical with expanding disclosure requirements and increasing demand trial transparency.

''
APR 08, 2025
Whitepaper
薬事規制関連支援サービス

Build vs. Buy: Choosing the Right Approach to Clinical Trial Disclosure

As global clinical trial transparency requirements evolve, sponsors must decide whether to build a disclosure management system or buy a vendor solution.

''
APR 14, 2025
Product Information
薬事規制関連支援サービス

Get the Answers You Need Faster – A Guide to Citeline Regulatory Solutions

Clinical trial disclosure can be a heavy burden for biopharma. This guide provides an overview of how Citeline helps throughout the regulatory process.

すべて表示